[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355075-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355075-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","microbiome-signatures-in-advanced-gastric-cancer-emerging-biomarkers-for-risk-stratification-therapy-guidance-and-prognostic-insight","Microbiome Signatures in Advanced Gastric Cancer - Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight","","Gastric cancer, commonly diagnosed at advanced or metastatic stages, poses a major clinical challenge and drives the need for biomarkers that enable earlier detection, reliable risk stratification, and personalized treatment optimization. Emerging evidence links gut microbiome dysbiosis with gastric cancer initiation, progression, and therapeutic responses. This review examines advanced/metastatic gastric microbiome-derived diagnostic and targetable biomarkers and their potential to guide immunotherapy response. Integrating microbiome profiling and therapeutic modulation strategies aims to improve patient outcomes and reduce toxicity.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/microbiome-signatures-in-advanced-gastric-cancer-emerging-biomarkers-for-risk-stratification-therapy-guidance-and-prognostic-insight/355075/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/microbiome-signatures-in-advanced-gastric-cancer-emerging-biomarkers-for-risk-stratification-therapy-guidance-and-prognostic-insight/355075.png","ImageObject",300,407,{"name":42,"@type":43},"Noah","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-10","2026-09-22",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How does the gut microbiome relate to advanced gastric cancer and its treatment?","Question",{"text":63,"@type":64},"Gut microbiome dysbiosis is associated with gastric cancer initiation and progression and with therapeutic outcomes. The review also links microbiome signals to modulation of immunotherapy responses.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Why are biomarkers needed for advanced gastric cancer?",{"text":68,"@type":64},"Advanced gastric cancer often lacks early signs, leading many cases to be diagnosed at nonresectable stages. Biomarkers are needed for early detection, risk stratification, and tailoring personalized therapy.",{"name":70,"@type":61,"acceptedAnswer":71},"What limits clinical translation of microbiome-based biomarkers?",{"text":72,"@type":64},"Clinical translation is hindered by methodological heterogeneity, limitations in establishing causality, and the lack of dedicated clinical trials.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355075,1790789646,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},8796095462418,"https://ap-avatar.wpscdn.com/avatar/80000253c1241d02b47?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778826106357471780","Review  \nMicrobiome Signatures in Advanced Gastric Cancer: Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight  \nKyung-il John Kim 1,†, Hannah Zhong 2,†, Derek Tai 3, Pranati Shah 3, Daniel Park 4, Vitor Goes 5, Jianan Li 6, Claire Jung 7, Lucas Kim 8, Sofia Guzman 9, Gagandeep Brar 9,* and Dani Castillo 9, *  \nAcademic Editors: Hirokazu Fukui and Changwon Yang  \nReceived: 10 September 2025  \nRevised: 21 January 2026  \nAccepted: 22 January 2026  \nPublished: 31 January 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Department of Internal Medicine, Kaiser Permanente Fontana Medical Center, 9961 Sierra Ave., Fontana, CA 92335, USA; [kyungil.j.kim@kp.org](kyungil.j.kim@kp.org)  \n2 Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, 1500 E Duarte Rd., Duarte, CA 91010, USA; [hazhong@coh.org](hazhong@coh.org)  \n3 Department of Internal Medicine, Loma Linda University Medical Center, 11234 Anderson St., Loma Linda, CA 92354, USA; [dtai@llu.edu](dtai@llu.edu) (D.T.); [pdshah@llu.edu](pdshah@llu.edu) (P.S.)  \n4 Department of Hematology and Oncology, Harbor-UCLA Medical Center, 1000 W Carson St., Torrance, CA 90502, USA; [dparkl7@dhs.lacounty.gov](dparkl7@dhs.lacounty.gov)  \n5 Department of Internal Medicine, Hospital Israelita Albert Einstein, Av. Albert Einstein, 627-Morumbi, São Paulo 05652-900, SP, Brazil; [vitor.goes@einstein.br](vitor.goes@einstein.br)  \n6 Faculty of Kinesiology & Physical Education, University of Toronto, 100 Devonshire Place, Toronto, ON M5S 2C9, Canada; [jianan.li@mail.utoronto.ca](jianan.li@mail.utoronto.ca)  \n7 Flintridge Preparatory School, 4543 Crown Ave., La Cañada Flintridge, CA 91011, USA; [28jungc@flintrridgeprep.org](28jungc@flintrridgeprep.org)  \n8 School of Medicine, Loma Linda University, 11175 Campus St., Loma Linda, CA 92350, USA; [lucaskim@students.llu.edu](lucaskim@students.llu.edu)  \n9 Department of Medical Oncology and Therapeutics Research, City of Hope, 1500 E Duarte Rd., Duarte, CA 91010, USA; [sofguzman@coh.org](sofguzman@coh.org)  \n* [Correspondence: gbrar@coh.org](Correspondence: gbrar@coh.org) (G.B.); [dacastillo@coh.org](dacastillo@coh.org) (D.C.)† These authors contributed equally to this work.  \nAbstract  \nGastric cancer (GC), often diagnosed at advanced or metastatic stages, remains a significant clinical challenge requiring novel biomarkers for early detection, risk stratification, and effective, personalized treatment optimization. Emerging evidence underscores a strong association between gut microbiome dysbiosis and GC initiation, progression, and therapeutic outcomes. This review explores the potential of the advanced/metastatic gastric microbiome as a source of diagnostic and targetable biomarkers and its role in modulating responses to immunotherapy. Although Helicobacter pylori (H. pylori) is the most significant risk factor for GC, several other gastrointestinal taxa—including Fusobacterium nucleatum (F. nucleatum)—have been implicated in advanced GC (AGC) . At its inception, microbial dysbiosis contributes to chronic inflammation and immune evasion, thereby influencing tumor behavior and treatment efficacy. Integrating microbiome-based biomarkers into risk stratification, GC staging, and targetable treatment frameworks may enhance early detection, inform immunotherapy strategies, and improve patient-specific treatment responses. Bifidobacterium and Lactobacillus rhamnosus GG have the potential to change the immunotherapy framework with their direct influence on dendritic cell (DC) and cytotoxic T cell (CTL) activity. However, clinical translation is impeded by methodological heterogeneity, causality limitations, and a lack of clinical trials. Nonetheless, the integration of microbiome profiling and the development of therapeutic microbiome modulati","cbCaieDCjkNC39nt","https://ap.wps.com/l/cbCaieDCjkNC39nt","pdf",682310,17,"English","# Introduction\n## Gastric cancer burden and advanced-stage risk\n## Gut and gastric microbiome dysbiosis in AGC\n## Microbiome biomarkers and precision oncology potential","[{\"question\":\"How does the gut microbiome relate to advanced gastric cancer and its treatment?\",\"answer\":\"Gut microbiome dysbiosis is associated with gastric cancer initiation and progression and with therapeutic outcomes. The review also links microbiome signals to modulation of immunotherapy responses.\"},{\"question\":\"Why are biomarkers needed for advanced gastric cancer?\",\"answer\":\"Advanced gastric cancer often lacks early signs, leading many cases to be diagnosed at nonresectable stages. Biomarkers are needed for early detection, risk stratification, and tailoring personalized therapy.\"},{\"question\":\"What limits clinical translation of microbiome-based biomarkers?\",\"answer\":\"Clinical translation is hindered by methodological heterogeneity, limitations in establishing causality, and the lack of dedicated clinical trials.\"}]","Microbiome Signatures in Advanced Gastric Cancer - Emerging Biomarkers for Risk Stratification, Therapy Guidance, and Prognostic Insight | PDF",1790115744,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/98a6684c9caae89be59574786db4a03a.webp",983,1390,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/707108dcbe16157fbaafc6345d14dcff.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6a98ebe19e9dd34123e76c4884bc1b4d.webp",981,1387,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/138125a089c3f364c9d3e603559dcd4f.webp",980,1385]